Assessment of Atrial Late Potentials in Patients with Hypercholesterolemia, to Investigate the Preventive Effect of Pitavastatin on Atrial Fibrillation.

Assessment of Atrial Late Potentials in Patients with Hypercholesterolemia, to Investigate the Preventive Effect of Pitavastatin on Atrial Fibrillation. - Assessment of Atrial Late Potentials in Patients with Hypercholesterolemia, to Investigate the Preventive Effect of Pitavastatin on Atrial Fibrillation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003824

Enrollment

Registered

2010-06-25

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Interventions

Pitavastatin 1-4 mg daily for a period of 12 months Non-statin treatment initially using ezetimibe 10 mg daily for a period of 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with hypercholesterolemia who have not attained the target LDL-C level established by the Japan Atherosclerosis Society guidelines for prevention of atherosclerotic cardiovascular diseases (2007). 2. Patients giving written consent on their own volition for participation in this clinical trial after being provided with sufficient explanation about the study.

Exclusion criteria

Exclusion criteria: 1. Patients who have a contraindication to LIVALO TAB administration. 2. Patients who have a contraindication to Zetia administration . 3. Patients who have a contraindication to LIPIDIL CAPSULE or Tricor Capsule administration. 4. Patients with liver dysfunction (AST or ALT values of >=100IU). 5. Patients being treated with statins. 6. Patients who are judged by the investigator to be not eligible for enrollment in the study.

Design outcomes

Primary

Measure	Time frame
Change in atrial late potentials recorded by P wave signal-averaged ECG.	—

Secondary

Measure	Time frame
1. Correlation between baseline characteristics and atrial late potentials. 2. Correlation between change in atrial late potentials and change in blood biomarkers.	—

Countries

Japan

Contacts

Public ContactYuji Okuyama

Osaka University Graduate School of Medicine Department of Advanced Cardiovascular Therapeutics

yujiokuyama@hotmail.com06-6879-3441

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026